Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

Completed · Phase 4

Conditions studied: Smoking

In brief

The major purpose of this exploratory developmental study will be to develop a patient-centered and feasible protocol for communicating genetic data as it relates to drug efficacy for smoking cessation inpatients receiving medication that is matched to individual genotypes associated with increased efficacy for bupropion or nicotine replacement therapy.

Key facts

Study ID

NCT00991081

Run by

Stanford University

People needed

36

Starts

2009-07-01

Expected to finish

2011-03-01

Last updated by the study team

2012-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (aged 18 or older)
• Currently smoke at least 10 cigarettes per day
• Motivated to quit smoking (>=5 on a 10-point Likert scale)
• Have a telephone
• Read and speak English.

You may not qualify if…

• Any medical contraindications for transdermal nicotine replacement therapy (NRT) or sustained-release bupropion hydrochloride (bupropion) use based on the package labels (e.g., for bupropion, risk of seizure)
• DSM-IV Axis I diagnosis (other than nicotine dependence)
• Subjects who meet criteria for current major depression, or who demonstrate evidence of suicidal ideation at screening will be referred to treatment for depression and will be excluded from the study
• Must agree not to seek other treatment for smoking cessation during the study.

Where it is running

• SRI International — Menlo Park, California, United States
• Stanford University School of Medicine — Stanford, California, United States
• Group Health Research Institute — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.